Shanghai Fosun Pharmaceutical and Fosun International have jointly submitted an application for the approval of the proposed spin-off and separate listing of biosimilars firm Shanghai Henlius Biotech on the main board of the Hong Kong Stock Exchange, according to a company statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
